New drug targets Hard-to-Treat colorectal cancer in early trial
NCT ID NCT07463599
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug, tegavivint, in people with metastatic colorectal cancer that has worsened after at least two prior treatments. The trial aims to find a safe dose and see if the drug shrinks tumors when used alone or with standard therapies. About 126 adults with specific gene mutations will participate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOMATOUS POLYPOSIS COLI (APC) GENE MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinical Trials Nurse Navigator
RECRUITINGScottsdale, Arizona, 85258, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Why are more younger adults getting colorectal cancer? a national study digs into the data
- Can two immune boosters outsmart Chemo-Resistant colon cancer?
- Can a Two-Pronged attack shrink Hard-to-Treat colorectal tumors?
- Can a Two-Drug attack shrink Hard-to-Treat colorectal tumors?
- Can a four-drug cocktail shrink hard-to-treat colorectal cancer?
- Can a Drug-Radiation combo outsmart Treatment-Resistant colorectal cancer?